Theravance Biopharma, Inc.TBPHNASDAQ
LOADING
|||
Switch Symbol:
Year-over-year gross profit growth rate
| Period | Value |
|---|---|
| Q3 2025 | -24.37% |
| Q2 2025 | 299.01% |
| Q1 2025 | -79.01% |
| Q4 2024 | 146.76% |
| Q3 2024 | 76.66% |
| Q2 2024 | -22.28% |
| Q1 2024 | -40.18% |
| Q4 2023 | -35.54% |
| Q3 2023 | 231.96% |
| Q2 2023 | 204.07% |
| Q1 2023 | -494.42% |
| Q4 2022 | -127.05% |
| Q3 2022 | 166.70% |
| Q2 2022 | 61.48% |
| Q1 2022 | 38.22% |
| Q4 2021 | 46.70% |
| Q3 2021 | 20.00% |
| Q2 2021 | 28.43% |
| Q1 2021 | -14.87% |
| Q4 2020 | -354.34% |
| Q3 2020 | 21.65% |
| Q2 2020 | -24.44% |
| Q1 2020 | -32.67% |
| Q4 2019 | 174.53% |
| Q3 2019 | -95.46% |
| Q2 2019 | 58.23% |
| Q1 2019 | -420.95% |
| Q4 2018 | 24.50% |
| Q3 2018 | 151.20% |
| Q2 2018 | -416.26% |
| Q1 2018 | 435.60% |
| Q4 2017 | -57.48% |
| Q3 2017 | 53.38% |
| Q2 2017 | -14.95% |
| Q1 2017 | -44.52% |
| Q4 2016 | -75.75% |
| Q3 2016 | 287.81% |
| Q2 2016 | -72.59% |
| Q1 2016 | 2447.98% |
| Q4 2015 | -93.16% |